Merck splits operations to separate oncology from non-cancer drugs
Reshuffle in preparation for 2028 US patent expiry of blockbuster cancer treatment Keytruda
Reshuffle in preparation for 2028 US patent expiry of blockbuster cancer treatment Keytruda
Acquisitions fuel pharma group’s evolution as it prepares to lose patent protection on cancer drug Keytruda
Quarterly proceeds from Keytruda top $8bn for first time
Terns Pharma stock has jumped since promising clinical data on its bone and blood cancer treatment last year
US company is attempting to acquire the maker of a new treatment for pancreatic cancer
A gathering of pharmaceutical executives comes as the sector has rebounded from uncertainty over Trump’s policies
Groups will need to buy mature biotechs to replace revenue lost to generic competitors
